Jefferies Group LLC Reaffirms Buy Rating for NantHealth Inc (NH)
Several other research firms also recently weighed in on NH. Canaccord Genuity reissued a buy rating and set a $6.00 price target (down previously from $8.00) on shares of NantHealth in a research report on Monday, August 21st. BidaskClub raised NantHealth from a sell rating to a hold rating in a research report on Friday, September 15th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $8.55.
Shares of NantHealth (NH) opened at 4.12 on Thursday. The stock’s market capitalization is $502.42 million. NantHealth has a 12 month low of $4.00 and a 12 month high of $13.96. The company’s 50 day moving average price is $4.41 and its 200 day moving average price is $4.41.
NantHealth (NYSE:NH) last released its quarterly earnings data on Thursday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.32). NantHealth had a negative net margin of 267.11% and a negative return on equity of 83.97%. The firm had revenue of $26.23 million during the quarter, compared to analysts’ expectations of $31.28 million. During the same period in the previous year, the business earned ($0.15) earnings per share. The business’s revenue for the quarter was down 16.7% on a year-over-year basis. Equities analysts anticipate that NantHealth will post ($0.70) earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System increased its position in NantHealth by 132.4% during the second quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock worth $134,000 after buying an additional 18,000 shares in the last quarter. State Street Corp increased its position in NantHealth by 88.1% during the second quarter. State Street Corp now owns 147,234 shares of the company’s stock worth $623,000 after buying an additional 68,963 shares in the last quarter. Goldman Sachs Group Inc. increased its position in NantHealth by 91.5% during the second quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock worth $717,000 after buying an additional 81,024 shares in the last quarter. Vanguard Group Inc. increased its position in NantHealth by 20.2% during the second quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock worth $1,792,000 after buying an additional 71,087 shares in the last quarter. Finally, Northern Trust Corp increased its position in NantHealth by 133.9% during the second quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock worth $643,000 after buying an additional 86,955 shares in the last quarter.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Stock Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related stocks with our FREE daily email newsletter.